MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-23-2522

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2024

Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials.

Svanberg Teglgaard Rebecca, Marquart Hanne Vibeke, Hartling Hans Jakob, Bay Jakob Thaning, da Cunha-Bang Caspar, Brieghel Christian, Faitová Tereza, Enggaard Lisbeth, Kater Arnon P, Levin Mark-David, Kersting Sabina, Ostrowski Sisse Rye, Niemann Carsten U

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Patients with chronic lymphocytic leukemia (CLL) have increased risk of severe infections. Although adaptive immune dysfunction is well described, clinical tools for identifying patients at risk are lacking, warranting investigation of additional immune components. In contrast to chemotherapy, targeted agents could spare or even improve innate immune function. Therefore, we investigated innate immune phenotypes and function in patients with CLL before and during targeted treatment.

EXPERIMENTAL

DESIGN

Baseline and consecutive blood samples were collected from patients with CLL treated with acalabrutinib (n = 17) or ibrutinib+venetoclax (n = 18) in clinical trials. Innate immune function was assessed by TruCulture, a whole-blood ligand-stimulation assay quantifying cytokine release in response to standardized stimuli. Innate immune phenotypes were characterized by flow cytometry. As a proxy for infections, we mapped antimicrobial use before and during treatment.

RESULTS

At baseline, patients with CLL displayed impaired stimulated cytokine responses to the endotoxin lipopolysaccharide (LPS) along with deactivated monocytes, enrichment of myeloid-derived suppressor cells and metamyelocytes, and elevated (unstimulated) proinflammatory cytokines. Two/three cycles of acalabrutinib or ibrutinib normalized LPS-stimulated responses, in parallel with decreased duration of infections. Innate immune profiles and elevated proinflammatory cytokines further normalized during longer-term acalabrutinib or ibrutinib+venetoclax, paralleled by decreased infection frequency.

CONCLUSIONS

Innate immune impairment and infection susceptibility in patients with CLL were restored in parallel during targeted therapy. Thus, targeted treatment may reduce the risk of infections in CLL, as currently under investigation in the PreVent-ACaLL phase 2 trial of acalabrutinib+venetoclax for high-risk CLL (NCT03868722).

Для цитирования: Svanberg Teglgaard Rebecca, Marquart Hanne Vibeke, Hartling Hans Jakob, Bay Jakob Thaning, da Cunha-Bang Caspar, Brieghel Christian, Faitová Tereza, Enggaard Lisbeth, Kater Arnon P, Levin Mark-David, Kersting Sabina, Ostrowski Sisse Rye, Niemann Carsten U. Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024. DOI: 10.1158/1078-0432.ccr-23-2522.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.